Harbour BioMed announces promising preclinical data for its first ai-enabled drug candidate
May 18, 2026 | 09:09
On 18 May 2026, the biotech firm revealed that LET003, an AI-discovered antibody targeting obesity, has potential to become a best-in-class therapy.
Latest News
Mobile Version